Table 2 Comparison of the clinical characteristics of good responders and poor responderss
Total (N = 102) | Good responders (N = 47) | Poor responders (N = 55) | p | |
|---|---|---|---|---|
Sex, N (%) | ||||
Male | 69 (67.6) | 28 (59.6) | 41 (74.5) | 0.11 |
Female | 33 (32.4) | 19 (40.4) | 14 (25.5) | |
Age (years), N (%) | ||||
< 65 | 80 (78.4) | 35 (74.5) | 45 (81.8) | 0.37 |
≥ 65 | 22 (21.6) | 12 (25.5) | 10 (18.2) | |
AV distance (cm), N (%) | ||||
< 5 | 62 (60.8) | 32 (68.1) | 30 (54.5) | 0.16 |
≥ 5 | 40 (39.2) | 15 (31.9) | 25 (45.5) | |
CEA level (ng/mL), N (%) | ||||
< 5 | 69 (67.6) | 30 (63.8) | 39 (70.9) | 0.45 |
≥ 5 | 33 (32.4) | 17 (36.2) | 16 (29.1) | |
cT stage, N (%) | ||||
T2 | 2 (2.0) | 1 (2.1) | 1 (1.8) | 0.17 |
T3 | 77 (75.5) | 38 (80.9) | 39 (70.9) | |
T4 | 23 (22.5) | 8 (17.0) | 15 (27.3) | |
cN stage, N (%) | ||||
Negative | 52 (51.0) | 26 (55.3) | 26 (47.3) | 0.42 |
Positive | 50 (49.0) | 21 (44.7) | 29 (52.7) | |
Clinical LPLN metastasis, N (%) | ||||
Negative | 78 (76.5) | 37 (78.7) | 41 (74.5) | 0.62 |
Positive | 24 (23.5) | 10 (21.3) | 14 (25.5) | |
Clinical CRM, N (%) | ||||
Negative | 73 (71.6) | 34 (72.3) | 39 (70.9) | 0.87 |
Positive | 29 (28.4) | 13 (27.7) | 16 (29.1) | |
mrEMVI, N (%) | ||||
Negative | 78 (76.5) | 38 (80.9) | 40 (72.7) | 0.34 |
Positive | 24 (23.5) | 9 (19.1) | 15 (27.3) | |
ymrEMVI, N (%) | ||||
Negative | 80 (78.4) | 39 (83.0) | 41 (74.5) | 0.30 |
Positive | 22 (21.6) | 8 (17.0) | 14 (25.5) | |